Infinity's IPI-504 featured in Journal of Medicinal Chemistry

By Elaine Rigoli

Tampa, Fla., July 27 - Infinity Pharmaceuticals, Inc. said Thursday that the July edition of Journal of Medicinal Chemistry, an official peer-reviewed journal of the American Chemical Society, has published a paper describing Infinity's water-soluble Hsp90 inhibitor, IPI-504, for the treatment of a broad range of cancers.

IPI-504 is being evaluated in two separate phase 1 clinical trials for the treatment of multiple myeloma and gastrointestinal stromal tumors.

The discovery of a water-soluble derivative of 17-AAG (17-Allylamino-17-demethoxy-geldanamycin) represents a significant breakthrough in Hsp90 inhibition, officials noted.

The 17-AAG pharmacophore, while a potent inhibitor of Hsp90, historically has suffered from pharmacological deficiencies - including poor solubility - which have necessitated the use of complex organic formulations with inherent patient-safety concerns, the company said in a news release.

The availability of a water-soluble derivative of 17-AAG allows Infinity, for the first time, to test the true potential of 17-AAG and its derivatives in inhibiting Hsp90, an important cancer target.

Infinity is a drug-development company located in Cambridge, Mass.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.